9.30 | 6.30 – Virtual Coffee Networking Morning

10.00 | 7.00 – Morning Chair’s Opening Remarks

Liquid Biopsies & Broadening Industry Applications

10.10 | 7.10 – Liquid Biopsy Assay Supporting Drug Development: Faster & Focused Enrollment

  • Carol Pena Executive Director, Translational Molecular Biomarkers and Diagnostics, Merck


  • Liquid biopsies to support identification of patient responders, speedy enrollment and ensure safety and efficacy in target population
  • What the successful and synchronized launch of both drug-Dx to market means for the future successes and applications of a therapeutic
  • Realizing the prognostic and predictive value of treatments via associated assays

10.40 | 7.40 – Bridging the GAP in Liquid Biopsies — CTCs & cfDNA: A Comprehensive Approach to Detection & Monitoring of Cancer


  • Cancer is a high complexity disease which requires a combination of biological insights from both genotypic and phenotypic analysis to guide precision medicine
  • Circulating tumor cells (CTCs) and cell free DNA (cfDNA) liquid biopsies enable complementary information for clinical decisions, allowing for diagnosis, accurate prognosis, therapeutic target selection, as well as monitoring response and resistance to treatment
  • Find out how these technologies enable a true Comprehensive Cancer Profiling from a single tube of blood to get all the biological insights needed

11.10 | 8.10 – Novel Biomarkers on the Horizon: Epigenetics to Detect Cancer Early

  • Ajay Goel Professor and Chair, Department of Molecular Diagnostics and Experimental Therapeutics, City of Hope


  • Discovery and development of new promising new biomarkers for screening and surveillance
  • Opportunities for future targeted therapy development
  • Early-detection only using ncRNAs and DNA methylation

11.40 | 8.40 – Session Reserved for Natera

12.10 | 9.10 – Speed Networking

12.40 | 9.40 – The Role of Minimum Residual Disease Detection for Therapeutic Development


  • How can MRD detection support therapeutic development
  • MRD from a Diagnostics perspective
  • Promoting timely and targeted interventions via liquid biopsy techniques

13.10 | 10.10 – Session Reserved for NeoGenomics Laboratories

13.40 | 10.40 – Interactive Roundtable: New Thinking for Liquid Biopsy Approaches

With two roundtables running in parallel, pick which conversation you would like to join and contribute to alongside your peers.

Which Indications Can Learn From Successes in Oncology?

• Liquid biopsy application in oncology is seeing successes in over 10 tumor types and holds great promise for the future, can other disease areas learn from these approaches?

• Adapting technologies for detection of circulating biomarkers of similar size in indications where existing diagnosis methods are inadequate /invasive

• What does the pandemic, and response from liquid biopsy leaders, tell us about the potential clinical utility of these technologies across today’s healthcare continuum

Jean-Francois Martini, Senior Director, Translational Oncology Lead, Global Product Development Pfizer

Taking a Holistic Look at Biomarker Approaches Using Liquid Biopsies

• An overview of cancer evolution, development and progression correlations

• Can taking a holistic view of past biological trends show new avenues for how to approach biomarker detection?

• A discussion forum for sharing new ideas and thinking strategically on the utility of circulating biomarkers

Yutaka Matsumoto, Senior Leader, Early Clinical Development Department, Translational Research Division Chugai Pharmaceutical Co., Ltd., Roche Group

14.25 | 11.25 – Panel Discussion: Starting With the End in Mind, Industry Collaboration for Industry Standards

  • Lauren Leiman Executive Director, BloodPAC
  • Darshana Jani Director, Bioanalytical & Biomarker Sciences, Agenus
  • Zheng Feng Director / Head of Molecular Biomarker & Genomics, Global Clinical Biomarkers & Companion Diagnostics, EMD Serono
  • Sunitha Nagrath Associate Professor, Chemical Engineering, University of Michigan


  • How can the industry better work together to unpick and target tumor heterogeneity?
  • What can we learn from past successful Drug-Dx collaborations?
  • Collaborations and partnering to support regulatory submission pathways

15.10 | 12.10 – Chair’s Closing Remarks: What’s Next For Liquid Biopsy in Precision Oncology


  • What new opportunities are there for liquid biopsies to further precision therapy approaches in oncology
  • What does clinical evidence show us in terms of liquid biopsy replacing the ‘gold standard’ become a reality in some instances – (Drawing on case study examples)
  • Reflecting on the core challenges industry needs to solve

15.30 | 12.30 – Networking & End of Day Two